

CADTH Reimbursement Reviews Expert Committee Meeting Schedule

Please consult the appropriate schedule for planning purposes:

- **Section 1:** Non-oncology drugs filed prior to October 26, 2020
- **Section 2:** Non-oncology drugs filed on or after October 26, 2020
- **Section 3:** Oncology drugs filed on or after October 20, 2020

Section 1: Non-Oncology Drugs Filed Prior to October 26, 2020

Submission Received ¹		Initiation Range ²		Expert Committee Meeting	Embargoed Recommendation Issued ³		Final Recommendation Issued ⁴	
From	To	From	To		From	To	From	To
Jul 24, 2020	Aug 27, 2020	Aug 11, 2020	Sep 14, 2020	Jan 20, 2021	Feb 01, 2021	Feb 03, 2021	Feb 23, 2021	Feb 25, 2021
Aug 28, 2020	Sep 24, 2020	Sep 15, 2020	Oct 09, 2020	Feb 17, 2021	Mar 01, 2021	Mar 03, 2021	Mar 22, 2021	Mar 24, 2021
Sep 25, 2020	Oct 23, 2020	Oct 13, 2020	Nov 09, 2020	Mar 17, 2021	Mar 29, 2021	Mar 31, 2021	Apr 20, 2021	Apr 22, 2021

¹ The date of receipt is considered day zero for the purpose of calculating the 10-business day targeted timeframe for the initial screening of the category 1 requirements. If the sponsor is targeting a specific meeting, they are encouraged to file the submission or resubmission early in the window to allow time for addressing any potential deficiencies in the requirements.

² Submissions and resubmissions are typically initiated within 10 business days of being accepted for review by CADTH.

³ For submissions that are filed on a pre-NOC basis, the embargoed recommendation will not be released until CADTH has received a copy of all required information, including a copy of the NOC or NOC/c.

⁴ The embargoed recommendation will not be released until all category 2 requirements have been received.

⁵ If the sponsor does not file a request for reconsideration or the drug plans have not filed a request for clarification.

Section 2: Non-Oncology Drugs Filed on or after October 26, 2020

Submission Received ¹		Initiation Range ²		Expert Committee Meeting	Draft Recommendation Issued ³		Final Recommendation Issued ⁴	
From	To	From	To		From	To	From	To
Oct 26, 2020	Nov 26, 2020	Nov 10, 2020	Dec 11, 2020	Apr 21, 2021	May 03, 2021	May 05, 2021	Jun 02, 2021	Jun 14, 2021
Nov 27, 2020	Dec 24, 2020	Dec 14, 2020	Jan 18, 2021	May 19, 2021	Jun 01, 2021	Jun 03, 2021	Jun 30, 2021	Jul 13, 2021
Jan 04, 2021	Jan 28, 2021	Jan 19, 2021	Feb 12, 2021	Jun 16, 2021	Jun 28, 2021	Jun 30, 2021	Jul 28, 2021	Aug 10, 2021
Jan 29, 2021	Mar 04, 2021	Feb 16, 2021	Mar 19, 2021	Jul 21, 2021	Aug 03, 2021	Aug 05, 2021	Sep 01, 2021	Sep 14, 2021
Mar 05, 2021	Mar 31, 2021	Mar 22, 2021	Apr 16, 2021	Aug 18, 2021	Aug 30, 2021	Sep 01, 2021	Sep 29, 2021	Oct 12, 2021
Apr 01, 2021	Apr 28, 2021	Apr 19, 2021	May 13, 2021	Sep 15, 2021	Sep 27, 2021	Sep 29, 2021	Oct 27, 2021	Nov 08, 2021
Apr 29, 2021	Jun 02, 2021	May 14, 2021	Jun 17, 2021	Oct 20, 2021	Nov 01, 2021	Nov 03, 2021	Nov 30, 2021	Dec 10, 2021
Jun 03, 2021	Jun 30, 2021	Jun 18, 2021	Jul 16, 2021	Nov 17, 2021	Nov 29, 2021	Dec 01, 2021	Jan 05, 2022	Jan 17, 2022
Jul 02, 2021	Jul 22, 2021	Jul 19, 2021	Aug 09, 2021	Dec 08, 2021	Dec 20, 2021	Dec 22, 2021	Jan 26, 2022	Feb 07, 2022

¹ The date of receipt is considered day zero for the purpose of calculating the 10-business day targeted timeframe for the initial screening of the requirements. If the sponsor is targeting a specific meeting, they are encouraged to file the application early in the window to allow time for addressing any potential deficiencies.

² Applications are typically initiated within 10 business days of being accepted for review by CADTH.

³ For submissions that are filed on a pre-NOC basis, the draft recommendation will not be released until CADTH has received a copy of all required information, including a copy of the NOC or NOC/c.

⁴ If there is no request for reconsideration filed by the sponsor and/or drug programs.

Section 3: Oncology Drugs Filed on or after October 20, 2020

Submission Received ¹		Initiation Range ²		Expert Committee Meeting	Draft Recommendation Issued ³		Final Recommendation Issued ⁴	
From	To	From	To		From	To	From	To
Oct 20, 2020	Nov 20, 2020	Nov 04, 2020	Dec 07, 2020	Apr 15, 2021	Apr 27, 2021	Apr 29, 2021	May 27, 2021	Jun 08, 2021
Nov 23, 2020	Dec 18, 2020	Dec 08, 2020	Jan 12, 2021	May 13, 2021	May 26, 2021	May 28, 2021	Jun 24, 2021	Jul 07, 2021
Dec 21, 2020	Jan 22, 2021	Jan 13, 2021	Feb 08, 2021	Jun 10, 2021	Jun 22, 2021	Jun 24, 2021	Jul 22, 2021	Aug 04, 2021
Jan 25, 2021	Feb 26, 2021	Feb 09, 2021	Mar 15, 2021	Jul 15, 2021	Jul 27, 2021	Jul 29, 2021	Aug 26, 2021	Sep 08, 2021
Mar 01, 2021	Mar 24, 2021	Mar 15, 2021	Apr 09, 2021	Aug 11, 2021	Aug 23, 2021	Aug 25, 2021	Sep 22, 2021	Oct 04, 2021
Mar 25, 2021	Apr 21, 2021	Apr 12, 2021	May 06, 2021	Sep 08, 2021	Sep 20, 2021	Sep 22, 2021	Oct 20, 2021	Nov 01, 2021
Apr 22, 2021	May 26, 2021	May 07, 2021	Jun 10, 2021	Oct 13, 2021	Oct 25, 2021	Oct 27, 2021	Nov 23, 2021	Dec 03, 2021
May 27, 2021	Jun 23, 2021	Jun 11, 2021	Jul 09, 2021	Nov 10, 2021	Nov 22, 2021	Nov 24, 2021	Dec 21, 2021	Jan 10, 2022
Jun 24, 2021	Jul 15, 2021	Jul 12, 2021	Jul 30, 2021	Dec 01, 2021	Dec 13, 2021	Dec 15, 2021	Jan 19, 2022	Jan 31, 2022

- ¹. The date of receipt is considered day zero for the purpose of calculating the 10-business day targeted timeframe for the initial screening of the requirements. If the sponsor is targeting a specific meeting, they are encouraged to file the application early in the window to allow time for addressing any potential deficiencies.
- ². Applications are typically initiated within 10 business days of being accepted for review by CADTH.
- ³. For submissions that are filed on a pre-NOC basis, the draft recommendation will not be issued until CADTH has received a copy of all required information, including a copy of the NOC or NOC/c.
- ⁴. If there is no request for reconsideration filed by the sponsor and/or drug programs.